Advance your oncology research and drug development with us. We use cutting-edge technology to create mouse models that better reflect human conditions, making them ideal for testing your agents. Using one of our innovative models we can perform the following services.
In Vivo Efficacy Testing Services
We have an array of preclinical services to evaluate the safety and efficacy of your compounds. Testing options include:
- Bispecific antibody assays
- CAR-T efficacy
- GvHD modeling and treatment
- Preclinical toxicity screening
- Immune checkpoint modulator evaluation
- huPBMC and huHSC reconstitution and efficacy testing
- Non-GLP toxicity studies
We offer additional services to ensure your research is comprehensive and complete.
Flow Cytometry: Our impressive flow cytometry platform has 4 lasers, 14 channels and can perform multi-color analysis. We can complete several analyses including:
- TIL analysis
- CBA cytokine assays
- Tumor associated antigen screening
- Binding assays
- Cell proliferation and cell toxicity assays
Histological Analysis: We can also collect and analyze your tissue samples. We offer specimen embedding and sectioning (paraffin and frozen), chemogenic staining, immunohistochemistry assays, retinal preparation and staining, and pathomorphological evaluation services.
Molecular Analysis: This includes RNA and protein extraction, qPCR, Western blots, and cytokine assays (ELISAs).
High Throughout Workflows: Our experienced team has established protocols to ensure we provide you with reliable, quality data quickly. Examples of our high throughput workflow services include:
- Performing large quantity dissections (~100 animals per day)
- Preparing hundreds of stained sections per week
- Completing pathological evaluation for more than 100 drug efficacy studies every year
IVIS Bioluminescence Imaging: Let us evaluate the therapeutic efficacy of your compounds. We provide high specificity, precise quantification, and quality imaging data (due to minimal background signaling) using our IVIS imaging platform.
Suggested Models for Preclinical Services
Human Immune System Reconstituted Mouse Models
Our reconstituted mouse models are created by transplanting human CD34+ hematopoietic stem cells or peripheral blood mononuclear cells into severe immunodeficient mice (e.g., NCG). Some of our most popular models include huPBMC-NCG, huHSC-NCG, huHSC-NCG-hIL15, huHSC-NCG-X. These models can be used in conjunction with our cell line-derived xenografts (CDX) or patient-derived xenografts (PDX) to investigate tumor growth and evaluate anti-tumor treatment options.
Humanized Immune Checkpoint Models
We have developed a series of proprietary humanized immune checkpoint mouse models on both BALB/c and C57BL/6 genetic backgrounds. The extracellular regions of the mouse immune checkpoints are replaced with the corresponding human fragments. These models are suitable for antibody efficacy and safety evaluation for cancer immunotherapy and other applications. To learn more click here.
In Vivo Tumor Models
In addition to our reconstituted mouse models, we also have in vivo tumor models.
Spontaneous Tumors: To date we have created several spontaneous tumor models for cancers frequently identified in humans including KPC pancreatic cancer, MMTV-PyMT breast cancer, and several KrasG12D models for lung, liver, and colon cancers. For a full list of spontaneous tumor models visit our Spontaneous Tumor page.
Syngeneic Tumors: We have an extensive library of wildtype and genetically engineered syngeneic tumor cell lines. Many of our models are created on both the BALB/c and B6 backgrounds, which allows you to select the best model for your research needs. BALB/c and C57BL/6 have different immune characteristics including varying expression levels of CD14, Toll Like Receptor and TGF beta, different sensitivity to carcinogens, and they respond differently to some viral infections. Please click here to see a list of available syngeneic mouse tumor cell lines.
Human Xenograft Models: Our human xenograft models have been generated by transferring human tumor tissue (e.g., cells, biopsies, whole organs) to a severe immunodeficient mouse (NCG or next-generation NCG) recipient.